A preclinical study written up by Peter Attia's research team reports that daily semaglutide given to aging mice was associated with a 12% longer median lifespan than in untreated controls, alongside better scores on several functional and molecular measures of aging.

The work was done entirely in female mice, and no human lifespan data exists. Treatment began at around 20 months of age, roughly equivalent to a 60-year-old human, with daily subcutaneous injections of 10 nmol/kg semaglutide or saline, a dose the analysis describes as producing clinically relevant exposure because rodents clear the drug far faster than people do.

Why the control group matters

The headline figure is 834 days of median survival in treated mice versus 742 days in controls. The complication, and the analysis is direct about it, is that 742 days is on the short side for this strain: female mice of the same strain reached a median of 866 days in a large Jackson Laboratory study, which puts the treated animals roughly where you would expect healthy mice to land anyway.

That leaves an alternative reading on the table. Rather than slowing aging, semaglutide may have offset some unrecognized factor depressing survival in this particular cohort, which is why the write-up calls for replication in an independent cohort at another institution.

Beyond the survival curve

In separate three-month cohorts, treated mice performed better than controls on spatial memory, exploratory behavior, motor coordination, endurance and glucose clearance. Tissue analysis found more cells expressing neurogenesis markers in the hippocampus and reduced expression of inflammatory cytokines and senescence markers, changes the authors present as correlates of aging rather than proof that a fundamental aging process was slowed.

Calorie restriction, or something else

Treated mice ate about 24% less food, which raises the obvious confound, since calorie restriction reliably extends mouse lifespan on its own. Researchers compared them with animals whose food was cut by a matching 24%: both groups lost similar weight and fat, but only the semaglutide group showed gains in memory, exploration and glucose control, and the calorie-restricted mice gorged then fasted while the drug-treated mice simply ate less throughout the day.

Where this leaves the question

The analysis calls the convergence of lifespan, function and molecular findings genuinely promising but not enough to establish semaglutide as a geroprotector. What it says is needed next: replication in both sexes, controls with more typical survival, and a calorie-matched lifespan arm.